Baidu
map

二甲双胍可降低原发性肝细胞癌的发病率

2012-04-10 庞琳娜 新华网

文献标题:Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis.[免费全文] 文献来源:Cancer Prev Res (Phila). 2012 Mar 31. 期刊影响因子:4.978       

文献标题:Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis.[免费全文]
文献来源:Cancer Prev Res (Phila). 2012 Mar 31.
期刊影响因子:4.978

       美国马里兰大学医学院研究人员日前公布研究报告称,他们完成的动物研究显示,常用糖尿病药物二甲双胍或许有助于预防原发性肝细胞癌。美国《癌症预防研究》杂志4月刊以封面文章的形式刊登了相关研究报告。
  
       研究人员培育了一批易患原发性肝癌的模型小鼠,然后给其中部分小鼠食物中添加二甲双胍。他们发现,服用二甲双胍的小鼠患原发性肝细胞癌的比例比对照组低57%;服药后仍患癌的小鼠肿瘤大小比对照组平均小37%。
二甲双胍在原发性肝细胞癌各细胞株中的抑制作用 
图 二甲双胍在原发性肝细胞癌各细胞株中的抑制作用
 
       领导研究的杰弗里·戈农表示,基于这项发现,医学界应该评估是否将二甲双胍列为原发性肝细胞癌的预防药物。   
       二甲双胍是一种具有长期用药安全记录的药品。此前曾有研究显示,二甲双胍可抑制肺部和乳腺肿瘤的生长,降低糖尿病患者患胰腺癌和乳腺癌的风险。
  
       原发性肝细胞癌是最常见的消化系统恶性肿瘤之一,Ⅱ型糖尿病患者患原发性肝癌的风险比普通人高2至3倍,其他高危人群包括肥胖者、肝炎以及非酒精性脂肪肝患者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846432, encodeId=15ed18464321e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Dec 11 04:37:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823145, encodeId=39fa182314552, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jun 04 06:37:00 CST 2012, time=2012-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863182, encodeId=2e2f1863182b2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 09 21:37:00 CST 2012, time=2012-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978311, encodeId=15fd19e831191, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat May 19 03:37:00 CST 2012, time=2012-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989746, encodeId=9ed71989e4629, content=<a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37091, encryptionId=91583e09134, topicName=原发性肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Jul 07 19:37:00 CST 2012, time=2012-07-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846432, encodeId=15ed18464321e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Dec 11 04:37:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823145, encodeId=39fa182314552, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jun 04 06:37:00 CST 2012, time=2012-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863182, encodeId=2e2f1863182b2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 09 21:37:00 CST 2012, time=2012-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978311, encodeId=15fd19e831191, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat May 19 03:37:00 CST 2012, time=2012-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989746, encodeId=9ed71989e4629, content=<a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37091, encryptionId=91583e09134, topicName=原发性肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Jul 07 19:37:00 CST 2012, time=2012-07-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846432, encodeId=15ed18464321e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Dec 11 04:37:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823145, encodeId=39fa182314552, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jun 04 06:37:00 CST 2012, time=2012-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863182, encodeId=2e2f1863182b2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 09 21:37:00 CST 2012, time=2012-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978311, encodeId=15fd19e831191, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat May 19 03:37:00 CST 2012, time=2012-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989746, encodeId=9ed71989e4629, content=<a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37091, encryptionId=91583e09134, topicName=原发性肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Jul 07 19:37:00 CST 2012, time=2012-07-07, status=1, ipAttribution=)]
    2012-05-09 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846432, encodeId=15ed18464321e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Dec 11 04:37:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823145, encodeId=39fa182314552, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jun 04 06:37:00 CST 2012, time=2012-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863182, encodeId=2e2f1863182b2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 09 21:37:00 CST 2012, time=2012-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978311, encodeId=15fd19e831191, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat May 19 03:37:00 CST 2012, time=2012-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989746, encodeId=9ed71989e4629, content=<a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37091, encryptionId=91583e09134, topicName=原发性肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Jul 07 19:37:00 CST 2012, time=2012-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846432, encodeId=15ed18464321e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Dec 11 04:37:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823145, encodeId=39fa182314552, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jun 04 06:37:00 CST 2012, time=2012-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863182, encodeId=2e2f1863182b2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 09 21:37:00 CST 2012, time=2012-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978311, encodeId=15fd19e831191, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat May 19 03:37:00 CST 2012, time=2012-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989746, encodeId=9ed71989e4629, content=<a href='/topic/show?id=91583e09134' target=_blank style='color:#2F92EE;'>#原发性肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37091, encryptionId=91583e09134, topicName=原发性肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Jul 07 19:37:00 CST 2012, time=2012-07-07, status=1, ipAttribution=)]

相关资讯

二甲双胍致乳酸性酸中毒的病例报告

引言二甲双胍是一种治疗2型糖尿病的口服降糖药物,1995年由美国食品和药品管理局(FDA)批准上市。英国前瞻性糖尿病研究(UKPDS)结果提供了很好的证据表明,二甲双胍对于超重患者糖尿病并发症的长期发病率具有有益作用 [1]。双胍类减少丙氨酸、丙酮酸和乳酸的糖异生。在某些情况下乳酸堆积可能会增加[2]。当谨慎使用时,二甲双胍引起乳酸性酸中毒是较为罕见的。乳酸性酸中毒较为罕见,但后果严重,死亡率高达

Kidney Int:对于2型糖尿病患者磺脲类药物致肾损伤的风险高于二甲双胍

  美国一项研究显示,与使用二甲双胍相比,口服磺脲类药物的2型糖尿病患者发生估计的肾小球滤过率(eGFR)下降、终末期肾脏病(ESRD)和死亡的风险增加。论文发表于4月期《国际肾脏病杂志》[Kidney Int 2012,81(7):698]。    

磺脲类药物致肾损伤的风险高于二甲双胍

    美国一项研究显示,与使用二甲双胍相比,口服磺脲类药物的2型糖尿病患者发生估计的肾小球滤过率(eGFR)下降、终末期肾脏病(ESRD)和死亡的风险增加。论文发表于4月期《国际肾脏病杂志》(Kidney Int. 2012 Apr;81(7):698-706.)。       研究纳入美国退伍军人管理局数据库中接受二甲双胍、磺酰脲或罗格列酮

Diabetes Care:长期应用二甲双胍可预防大鼠慢性心衰发生

  意大利学者的一项研究表明,在自发性高血压和胰岛素抵抗大鼠遗传模型(SHHF)中,长期应用二甲双胍可通过多种相互作用来预防严重慢性心衰发生。论文于2012年2月16日在线发表于《糖尿病护理》(Diabetes Care)杂志。   胰岛素抵抗是近期确认的涉及慢性心衰病理生理学的发病机制。此项研究将30只SHHF大鼠随机分入二甲双胍、罗格列酮和无药物治疗三组,并以10只SD大鼠作为正常

CPR:二甲双胍可能有助于原发性肝癌的预防

美国马里兰大学医学院研究人员日前公布研究报告称,他们完成的动物研究显示,常用糖尿病药物二甲双胍或许有助于预防原发性肝癌。美国《癌症预防研究》杂志4月刊以封面文章的形式刊登了相关研究报告。近年来研究表明,糖尿病可能是肿瘤的易发因素之一,因此,降糖药物二甲双胍被认为可能具有预防肿瘤的潜力。 研究人员培育了一批易患原发性肝癌的模型小鼠,然后给其中部分小鼠食物中添加二甲双胍。他们发现,服用二甲双胍的

二甲双胍通过miRNA抑制胰腺癌干细胞,治疗胰腺癌

二甲双胍是降糖药物中少见的具有抗癌功能,但是其作用机制一直不明。以前研究表明,二甲双胍能降低胰腺癌风险,以及二甲双胍能杀伤肿瘤干细胞的作用。这项研究进一步研究二甲双胍杀伤肿瘤干细胞的机制。 作者以microRNA为突破口,发现二甲双胍能够下调肿瘤干细胞的标志物,如CD44,EpCAM,EZH2, Notch-1, Nanog 和Oct4表达,同时, 能够恢复一些与抑癌有关miRNA表达,包括le

Baidu
map
Baidu
map
Baidu
map